Correspondence 0001493152-23-021610 from Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma Holdings, Inc.
Date: June 16, 2023 · CIK: 0001582554 · Accession: 0001493152-23-021610

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-272580

Date

June 9, 2023

Author

Chief

Form

CORRESP

Company

Matinas BioPharma Holdings, Inc.

Letter

Matinas BioPharma Holdings, Inc.

Route 206 South, Suite 302

Bedminster, New Jersey 07921

June 16, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: Matinas BioPharma Holdings, Inc.

Registration Statement on Form S-3 (File No. 333-272580)

Filed on June 9, 2023

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, Matinas BioPharma Holdings Corp. hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on June 20, 2023, or as soon as practicable thereafter.

Please call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with any questions.

Very
truly yours,
MATINAS
BIOPHARMA HOLDINGS, INC.

Show Raw Text

CORRESP
1
filename1.htm

Matinas
BioPharma Holdings, Inc.

1545
Route 206 South, Suite 302

Bedminster,
New Jersey 07921

June
16, 2023

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    Matinas
    BioPharma Holdings, Inc.

    Registration
    Statement on Form S-3 (File No. 333-272580)

    Filed
    on June 9, 2023

Ladies
and Gentlemen:

In
accordance with Rule 461 under the Securities Act of 1933, as amended, Matinas BioPharma Holdings Corp. hereby requests that the above-referenced
Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission
at 4:00 p.m., Eastern Time, on June 20, 2023, or as soon as practicable thereafter.

Please
call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with any questions.

    Very
    truly yours,

    MATINAS
    BIOPHARMA HOLDINGS, INC.

    By:
    /s/
    Jerome D. Jabbour

    Name:
    Jerome
    D. Jabbour

    Title:
    Chief
    Executive Officer

SecProbe.io